The potential of a universal influenza virus-like particle vaccine expressing a chimeric cytokine
Open Access
- 7 November 2022
- journal article
- research article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (1) , e202201548
Abstract
The efficacy of the current influenza vaccines is frequently reduced because of antigenic drift, a trade-off of developing improved vaccines with broad cross-protective activity against influenza A viruses. In this study, we have successfully constructed a chimeric cytokine (CC) comprising the M2 protein, influenza A neuraminidase stalk, and interleukin-12. We produced virus-like particles (VLPs) containing CC and influenza hemagglutinin (HA) proteins using a baculovirus system in Eri silkworm pupae. The protective efficacy of the CCHA-VLP vaccine was evaluated in mice. The CCFkH5HA-VLP vaccine increased the survival rates of BALB/c mice, infected with a lethal dose of PRH1 and HKH5 viruses, to 80% and 100%, respectively. The results suggested that CCHA-VLP successfully induced potent cross-reactive protective immunity against infection with homologous and heterologous subtypes of the influenza A virus. This is the first study to design a CC-containing HA-VLP vaccine and validate its protective efficacy.Keywords
Funding Information
- Shinshu University
This publication has 19 references indexed in Scilit:
- Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c miceVaccine, 2016
- The large-scale production of an artificial influenza virus-like particle vaccine in silkworm pupaeVaccine, 2015
- Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccinesVirology Journal, 2014
- Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adultsVaccine, 2011
- Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypesProceedings of the National Academy of Sciences, 2010
- Interleukin-12 as an adjuvant for induction of protective antibody responsesCytokine, 2010
- Interleukin-12: Biological Properties and Clinical ApplicationClinical Cancer Research, 2007
- A universal influenza A vaccine based on the extracellular domain of the M2 proteinNature Medicine, 1999
- Characteristics of Cytotoxic T Lymphocytes Directed to Influenza Virus Haemagglutinin Elicited by Immunization with Muramyldipeptide‐Influenza Liposome VaccineScandinavian Journal of Immunology, 1995
- Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.Journal of Experimental Medicine, 1989